anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ABSTRACT OF THE DISCLOSURE    Ethylene oxide (EO) adducts of di- and tri-functional starters, such as, trimethylolpropane and glycerine, provide unexpected improvements in the "wet compression set" properties of high resilience (HR) urethane foams.  Heretofore, wet set improvements have been achieved through the use of EO adducts of tetrols because of the high degree of crosslink density which these materials impart to a urethane polymeric composition. One commercial wet set additive, which is an EO adduct of pentaerythritol and diglycerine, is an effective wet set improver.  Surprisingly, EO adducts of di- and tri-functional starters provide improvements in foam wet set properties, which are comparable to those obtained with such commercial wet set additive.   Specifically, EO adducts of glycerine in the 500 to 10,000 molecular weight range yield foam wet set improvements equal to those of such commercial wet set additive at as low as 20 percent of the use level on an equivalent weight basis. Moreover, the EO adducts of glycerine yield foams having improved elongation properties and improved processing (stability) characteristics as compared to those observed with such commercial wet set additives.  An EO adduct of glycerine having a number average MW of 1,000 is particularly useful in the invention.
Conventional perioperative counseling and regular fasting food for 12 hours and water for 6 hours before surgery. Lie down and oral intake at least 4 hours after recovery. An electronic analgesic pump containing opioids drug and Flubiprofen Axetil in this group for postoperative pain management.
Therapy with oral glucocorticoids often plays an important role in the management of rheumatoid arthritis (RA). The American College of Rheumatology (ACR) Ad Hoc Committee on Clinical Guidelines recently concluded that glucocorticoids are highly effective in relieving symptoms among people with active RA and that these medications may retard the rate of joint damage. Despite these obvious benefits, therapy with oral glucocorticoids is a well-established risk factor for osteoporosis, as highlighted by the recently published ACR Guidelines on the Prevention of Glucocorticoid-induced Osteoporosis. The ultimate objective of the proposed research is to improve the health-related quality of life of individuals with RA by reducing their risk of developing osteoporosis secondary to glucocorticoid therapy. The study has four specific aims: (1) to obtain descriptive information concerning patients' knowledge, beliefs and behaviors with respect to osteoporosis and osteoporosis prevention; (2) to identify factors that discriminate among patients in different stages of change with respect to each behavior of interest; (3) to compare the effects of tailored versus generic educational materials on patient adherence to the ACR Guidelines for the Prevention Glucocorticoid-induced Osteoporosis; and (4) to determine if the effects of tailored educational materials is enhanced by concurrent feedback of information concerning patients' behavioral risk factor status to their physicians. A sample of 273 patients with RA currently taking an oral glucocorticoid were recruited to participate in the study. Data were collected via mailed questionnaires and telephone interviews. The study used an experimental research design. Following baseline data collection, participants were randomly assigned to one of four experimental groups. Patients in one group received standard care only. Patients in the second group received generic educational materials about osteoporosis and osteoporosis prevention in addition to standard care. Patients in the third group received educational materials tailored to their stage in the behavior change process in addition to standard care. Finally, patients in the fourth group received the same tailored educational materials and care received by patients in the third group. In addition, each patient's physician received feedback concerning the patient's status with respect to behavioral risk factors for osteoporosis (e.g., inadequate calcium intake). Follow-up data were collected one year after baseline data collection. Variables assessed included: (1) behavior, (2) stage of change, (3) knowledge and counseling received concerning osteoporosis, (4) health beliefs, (5) physical health status, (6) osteoporosis risk factors, (7) background characteristics, and (8) information seeking. To accomplish the specific aims of the study, data will be analyzed using descriptive statistics, multivariate analysis of variance, and discriminant analyses.
The study design is based on measuring the depth of ischemia during the operation, which is compared to the intraoperative and postoperative morbidity of the patient, especially to the dysfunction of the heart. A qualified and experienced Monitor is assigned for the study to oversee and document the progress of the trial. The Monitor ensures the trial performance in accordance with the Protocol and Good Clinical Practice (GCP). The trial team conforms to ISO 13485 quality standards and ISO 14155 GCP. Processes included in the monitoring activities are documented in the quality management system. Below are described the summaries of all these activities. Source data will be collected and transferred into the electronic CRFs by site staff, and the collected data quality and the conformity to the Good Clinical Practice will be assessed by monitoring. Based on a risk assessment performed, a Data Monitoring Committee shall not be established. Clinical Research Associate (CRA) is responsible for checking the accuracy and completeness of Case Report Form (CRF) entries, source documents, and other investigation-related records against each other. Other responsibilities of CRA, including detailed Source Data Verification (SDV), are documented by the clinical project manager (CPM) or head of clinical research (HCR)(both are sponsor's representatives). SDVs will be performed and documented during monitoring visits. Monitoring planning, reporting, and visits are pre-defined and documented with pre-made templates per the sponsor's quality management system. Monitoring visits will be performed to cover data from all study participants, and according to QMS and the Standard Operation Procedures. The monitoring shall ensure that all source documentation is precise and document control is exercised in all relevant documentation. The monitoring ensures, that the Adverse events are always reported and appropriate authorities or stakeholders are informed.
Carcinogenesis

Long-term studies to evaluate the carcinogenic potential of hydromorphone hydrochloride were completed in both Han-Wistar rats and Crl:CD1®(ICR) mice. Hydromorphone HCl was administered to Han-Wistar rats (2, 5, and 15 mg/kg/day for males, and 8, 25 and 75 mg/kg/day for females) for 2 years by oral gavage. In female rats, incidences of hibernoma (tumor of brown fat) were increased at 10.5 times the maximum recommended daily exposure based on AUC at the mid dose (2 tumor, 25 mg/kg/day) and 53.7 times the maximum recommended human daily exposure based on AUC at the maximum dose (4 tumors, 75 mg/kg/day). The clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in male rats. The systemic drug exposure (AUC, ng•h/mL) at the 15 mg/kg/day in male rats was 7.6 times greater than the human exposure at a single dose of 32 mg/day of hydromorphone hydrochloride extended-release tablets. There was no evidence of carcinogenic potential in Crl:CD1®(ICR) mice administered hydromorphone HCl at doses up to 15 mg/kg/day for 2 years by oral gavage. The systemic drug exposure (AUC, ng•h/mL) at the 15 mg/kg/day in mice was 1.1 (in males) and 1.2 (in females) times greater than the human exposure at a single dose of 32 mg/day of hydromorphone hydrochloride extended-release tablets.

Mutagenesis 

Hydromorphone was not mutagenic in the in vitro bacterial reverse mutation assay (Ames assay). Hydromorphone was not clastogenic in either the in vitro human lymphocyte chromosome aberration assay or the in vivo mouse micronucleus assay.

Impairment of Fertility 

Reduced implantation sites and viable fetuses were noted at 2.1 times the human daily dose of 32 mg/day in a study in which female rats were treated orally with 1.75, 3.5, or 7 mg/kg/day hydromorphone hydrochloride (0.7, 1.4, or 2.8 times a human daily dose of 24 mg/day (HDD) based on body surface area) beginning 14 days prior to mating through Gestation Day 7 and male rats were treated with the same hydromorphone hydrochloride doses beginning 28 days prior to and throughout mating.
PROBLEM TO BE SOLVED: To obtain a hair cosmetic which imparts luster and body to the hair, assures smooth combing, and gives luster and wiriness, particularly when used on the hair run dry due to damage. SOLUTION: This hair cosmetic contains lactic acid or a salt thereof with a higher content ratio of L-lactic acid than that of D-lactic acid. More particularly, the content ratio of L-lactic acid based on the total amount of the lactic acid is preferably between 60 and 100%. Additionally, the content of the lactic acid based on the total weight of the composition is preferably >=0.005wt.%, a particularly >=0.05wt.%. In case the hair cosmetic is to be rinsed off, the effect of high content ratio of L-lactic acid is further improved by using an anionic surfactant, ampholytic surface or nonionic surfactant as the cleansing agent for the hair surface. Furthermore, a conditioning agent may be added to the system.
Repetitive transcranial magnetic stimulation (rTMS) is an established therapy for treatment-resistant depression. The approved method for treatment is 10Hz stimulation for 40 min over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been effective in real world situations. The limitations of this approach include the duration of the treatment (approximately 40 minutes per treatment session, 5 days per week, for 4-8 weeks). Recently, we have pursued modifying the treatment parameters to reduce treatment times with an accelerated treatment paradigm with great preliminary success. This study aims to further study our accelerated protocol and examine changes in neuroimaging biomarkers.

Dr. Nolan Williams is the Principle Investigator on the grant associated for this study and so is listed as Study Director on the study record.
1. Technical Result There is made a plant-based medicament for enhancing and controlling the tone of smooth-muscle organs with a limited number of biologically active substances. 2. Essence A medicament contains Iberis amara, preferably Iberis amara totalis (flowers, seeds, leaves, stalks and roots) in the form of an extract as the sole component producing the action or a mixture, preferably in the form of extracts, as the sole component producing the action, one or more plants selected from the group: Menthae piperitae, preferably Menthae piperitae folium, Matricariae, preferably Matricariae flos, Carvi fructus, Melissae folium, Liquiritae radix. 3. Field of Application Medicine, therapy. Figures:  7
This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
INTRODUCTION: The management of even large pericardial effusions in asymptomatic patients is still a matter of debate. Aim of the present study is to explore, in a multicenter setting, the rate of post-cardiac injury syndromes (PCIS) and pericardial effusion recurrence after pericardial effusion drainage procedure.
MATERIAL AND METHODS: This is a multicenter international retrospective study including a consecutive cohort of patients diagnosed with large, chronic and idiopathic pericardial effusions, prospectively evaluated from January 2003 to December 2021 who underwent a clinically indicated pericardial drainage procedure. Two separate end-points were recorded: 1) recurrence of pericardial effusion after drainage without any sign of pericardial inflammation 2) occurrence of PCIS, defined as the new onset of pericarditis 1 to 6 weeks after pericardial intervention.
RESULTS: 124 patients were enrolled (50 % female, mean age 64 years old). A mean follow-up of 29.6 ± 25.6 months was obtained in 110 patients (88 %). 110 patients were treated with pericardiocentesis (89 %), 25 with pleuro-pericardial windows (20 %), and 1 with pericardiectomy (1 %). PCIS occurred in 21 out of 124 patients followed for at least 6 weeks (16.9%). Recurrence of pericardial effusion after drainage without any sign of pericardial inflammation occurred in 68 out of 110 patients at a longer follow-up (61.8 %). At multivariate analysis only inflammatory cells in pericardial fluid was associated with PCIS and pericardiocentesis with pericardial effusion recurrency.
CONCLUSION: Our data support the need of caution with the use of pericardiocentesis in asymptomatic patients with large pericardial effusion as it is often associated with pericardial effusion recurrence. Of interest the presence of inflammatory cells in the pericardial fluid is associated with PCIS after pericardial drainage procedures.
In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
AIM: To examine the anatomy of the petrosphenoidal ligament (PSL), and its relationship with the abducens nerve (AN) in newborn cadavers.
MATERIAL AND METHODS: Using 10 formalin-fixed newborn cadavers, 20 PSLs and ANs on both sides were examined. The structure of each PSL, its morphometric features, and its relationship with the AN were evaluated. For the morphometric measurements, photographs were taken in macro mode and then the ImageJ program was used.
RESULTS: The PSL was usually shaped like a butterfly. The structures of all the ligaments were complete. The PSL was attached to the petrous apex posteriorly and to the clivus or posterior clinoid process (PCP) anteriorly. The mean PSL length was 6.58 ± 1.4 mm. The mean width of the ligament's attachment to the petrous apex was 3.12 ± 0.63 mm. The mean width of the ligament's attachment to the PCP or clivus was 3.12 ± 0.5 mm. The AN was located below the PSL in all the samples. It was usually situated in the 1/3 lateral part under the PSL (70%). The mean diameter of the AN, as located under the ligament, was 0.8 ± 0.12 mm.
CONCLUSION: The PSL serves as an important anatomical landmark in the petroclival region. In addition, AN is closely adjacent to many anatomical structures such as the trigeminal nerve and internal carotid artery. The increased knowledge obtained through this study on newborn cadavers concerning the anatomy of the PSL and its relationship with the AN will help increase the success of surgical procedures and reduce surgical complications.
Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
Disclosed herein, among other things, are compositions and methods for using human isolated or synthetic alcaligenes faecalis, bacillus highland, bacillus pumilus, bacillus subtilis, or bacillus deep blue-violet. The composition can improve skin health. The method may comprise applying human isolated or synthetic alcaligenes faecalis, bacillus highland, bacillus pumilus, bacillus subtilis, or bacillus deep blue-violet to the host or host area (e.g., skin or mucosa) to minimize the presence of one or more pathogenic microorganisms, maximize the therapeutic effect of one or more additional therapeutic agents, and/or improve the health of the host or host area. Methods of minimizing pathogenic microorganisms can include applying to a surface a composition comprising human isolated or synthetic alcaligenes faecalis, bacillus highland, bacillus pumilus, bacillus subtilis, or bacillus deep blue-violet, and an acceptable carrier. The compositions and methods may include a prebiotic or another microorganism to maximize growth and/or metabolites (e.g., metabolites produced by the growth of the probiotic). The compositions and methods may include human isolated or synthetic alcaligenes faecalis, bacillus highland, bacillus pumilus, bacillus subtilis, or a deep blue violet bacillus metabolite.
Participants with parkinson's disease will be administered Equfina 50 milligram (mg) tablets, orally, once daily in combination with levodopa-containing products. On the basis of symptoms, Equfina 100 mg tablet, orally, once daily may be selected for participants. All the participants will be observed for up to 24 weeks prospectively.
Trained 3 times per week on non-consecutive days for 6 weeks for a total of 18 training sessions. UNS training consisted in the following three exercises: 1) One leg squat: Standing on the floor on one leg only and squat down until knee flexed to 900 and press back up with just that single leg. 2) One leg Squat on Bosu® balance Trainer: Standing on the Bosu® balance Trainer on one leg only and squat down until supported leg knee flexes to 900 and press back up with just that single leg. 3) Forward lunges on a Bosu® balance Trainer: position the forward leg on the Bosu® balance Trainer and squatting with the forward leg.
Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE mediated food allergy presenting with delayed onset of projectile vomiting in the absence of cutaneous and respiratory symptoms. The pathophysiology of FPIES remains poorly characterized. The first international consensus guidelines for FPIES were published in 2017 and provided clinicians with parameters on the diagnosis and treatment of FPIES. The guidelines have served as a resource in the recognition and management of FPIES, contributing to an increased awareness of FPIES. Since then, new evidence has emerged, shedding light on adult-onset FPIES, the different phenotypes of FPIES, the recognition of new food triggers, center-specific food challenge protocols and management of acute FPIES. Emerging evidence indicates that FPIES impacts both pediatric and adult population. As a result, there is growing need to tailor the consensus guidelines to capture diagnoses in both patient groups. Furthermore, it is crucial to provide food challenge protocols that meet the needs of both pediatric and adult FPIES patients, as well as the subset of patients with atypical FPIES. This review highlights the evolving clinical evidence relating to FPIES diagnosis and management published since the 2017 International FPIES Guidelines. We will focus on areas where recent published evidence may support evolution or revision of the guidelines.
Non-adherence to oral medications is a prevalent problem in adolescents and young adults (AYA) with cancer that may impact both survival and quality of life while on treatment. The purpose of this study is to explore use of a smart-phone medication reminder application to promote adherence to oral medications by AYA with cancer. The study's primary aim is to explore the feasibility and acceptability of using a smart-phone medication reminder application to promote adherence to oral medications by AYA with cancer as well as to characterize application use. Secondary aims include: 1) to obtain initial estimates of intervention effect- measured by pre-intervention to post-intervention differences in perceived behavioral control for adherence, intention to adhere, and adherence behavior - to inform design of a future trial powered to detect a clinically significant effect of smart-phone medication reminder application use on adherence to oral medications; and 2) to examine the relationships among perceived behavioral control for adherence, intention to adhere, and adherence behavior. A pre-post single group design will be used. Data will be collected weekly for 4 weeks before introduction of the intervention and for 8 weeks following introduction of the intervention. Analytic approaches will include descriptive statistics and generalized estimating equation (GEE) modeling.
A nanoparticle complex contains short-interfering RNA (siRNA) and one or more amino acid derivatives. The nanoparticles may be spherical or micelle-like. The complex may have a mixture of spherical/micelle-like and fibril-like nanoparticles, or a mixture of spherical/micelle-like, sheet-like and/or fibril-like nanoparticles. The complexes may be used as part of a method of delivering RNA or DNA into a cell, where the RNA or DNA is mixed with one or more amino acid derivatives, the mixture is diluted into a cell culture medium, and a cell is dosed with the diluted mixture. The RNA may be small interfering RNA (siRNA). The method may reduce messenger RNA (mRNA) levels and/or protein levels related to a specific gene or genes by at least 50% and exhibit cell viabilities equal to or exceeding 40% after 48 hours.
The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway. Taken together, the present invention provide the strong evidence that the pharmaceutical composition, including inhibitors for TIP41 expression or activity can be used for cancer prevention and treatment as well as an anti-cancer adjuvant. Taken together, the pharmaceutical composition comprising inhibitors for expression or activity of TIP41 protein may be used for prevention and treatment of cancer or as an anti-cancer adjuvant.
Disclosed are a radioactive carbon microsphere injection, a preparation method, and a use, related to the field of pharmaceutical technology. Each 1 ml of radioactive carbon microsphere injection comprises: 0.1 to 300 mg of radioactive carbon microspheres and 1 to 0.8 ml of a hydrogel. The injection is used for the preparation of medications that treat tumors, and can be directly injected into a tumor by interventional means, allowing for direct determination, according to the administration volume, of the radioactive dosage of the radioactive carbon microspheres. Hydrogel that has reached inside of the tumor can, together with calcium ions, form a gel inside of the tumor, so that the radioactive carbon microspheres can be dispersed relatively uniformly and be limited in the tumor. The radioactive carbon microspheres provide high-dosage local radiation therapy to implement the treatment of a solid tumor. The present invention has wide application prospect in solid tumor treatment.